Dr Leanne Mooney
- Honorary Clinical Research Fellow (School of Cardiovascular & Metabolic Health)
Publications
2025
Elbassioni, A. A. M. et al. (2025) Targeting Runx1 protects against heart failure with preserved ejection fraction. bioRxiv, (doi: 10.1101/2025.01.24.634831)
2023
Mooney, Leanne, Jackson, Colette E., Adamson, Carly, McConnachie, Alex ORCID: https://orcid.org/0000-0002-7262-7000, Welsh, Paul
ORCID: https://orcid.org/0000-0002-7970-3643, Myles, Rachel C.
ORCID: https://orcid.org/0000-0003-4670-361X, McMurray, John J.V.
ORCID: https://orcid.org/0000-0002-6317-3975, Jhund, Pardeep S.
ORCID: https://orcid.org/0000-0003-4306-5317, Petrie, Mark C.
ORCID: https://orcid.org/0000-0002-6333-9496 and Lang, Ninian N.
ORCID: https://orcid.org/0000-0001-8441-6887
(2023)
Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction.
Circulation: Heart Failure, 16(4),
e010051.
(doi: 10.1161/CIRCHEARTFAILURE.122.010051)
(PMID:36896709)
(PMCID:PMC10101136)
2022
Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)
2021
Mooney, L. et al. (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. Journal of the American Heart Association, 10(23), e021494. (doi: 10.1161/JAHA.121.021494) (PMID:34796742) (PMCID:PMC9075384)
Mooney, Leanne, Goodyear, Carl S. ORCID: https://orcid.org/0000-0001-5926-5941, Chandra, Tamir, Kirschner, Kristina
ORCID: https://orcid.org/0000-0001-7607-8670, Copland, Mhairi
ORCID: https://orcid.org/0000-0002-7655-016X, Petrie, Mark C.
ORCID: https://orcid.org/0000-0002-6333-9496 and Lang, Ninian N.
ORCID: https://orcid.org/0000-0001-8441-6887
(2021)
Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure.
Clinical Science, 135(7),
pp. 991-1007.
(doi: 10.1042/CS20200306)
(PMID:33861346)
(PMCID:PMC8055963)
Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)
2019
Ferry, A. V. et al. (2019) Presenting symptoms in men and women diagnosed with myocardial infarction using sex‐specific criteria. Journal of the American Heart Association, 8(17), e012307. (doi: 10.1161/JAHA.119.012307) (PMID:31431112) (PMCID:PMC6755854)
Articles
Elbassioni, A. A. M. et al. (2025) Targeting Runx1 protects against heart failure with preserved ejection fraction. bioRxiv, (doi: 10.1101/2025.01.24.634831)
Mooney, Leanne, Jackson, Colette E., Adamson, Carly, McConnachie, Alex ORCID: https://orcid.org/0000-0002-7262-7000, Welsh, Paul
ORCID: https://orcid.org/0000-0002-7970-3643, Myles, Rachel C.
ORCID: https://orcid.org/0000-0003-4670-361X, McMurray, John J.V.
ORCID: https://orcid.org/0000-0002-6317-3975, Jhund, Pardeep S.
ORCID: https://orcid.org/0000-0003-4306-5317, Petrie, Mark C.
ORCID: https://orcid.org/0000-0002-6333-9496 and Lang, Ninian N.
ORCID: https://orcid.org/0000-0001-8441-6887
(2023)
Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction.
Circulation: Heart Failure, 16(4),
e010051.
(doi: 10.1161/CIRCHEARTFAILURE.122.010051)
(PMID:36896709)
(PMCID:PMC10101136)
Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)
Mooney, L. et al. (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. Journal of the American Heart Association, 10(23), e021494. (doi: 10.1161/JAHA.121.021494) (PMID:34796742) (PMCID:PMC9075384)
Mooney, Leanne, Goodyear, Carl S. ORCID: https://orcid.org/0000-0001-5926-5941, Chandra, Tamir, Kirschner, Kristina
ORCID: https://orcid.org/0000-0001-7607-8670, Copland, Mhairi
ORCID: https://orcid.org/0000-0002-7655-016X, Petrie, Mark C.
ORCID: https://orcid.org/0000-0002-6333-9496 and Lang, Ninian N.
ORCID: https://orcid.org/0000-0001-8441-6887
(2021)
Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure.
Clinical Science, 135(7),
pp. 991-1007.
(doi: 10.1042/CS20200306)
(PMID:33861346)
(PMCID:PMC8055963)
Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)
Ferry, A. V. et al. (2019) Presenting symptoms in men and women diagnosed with myocardial infarction using sex‐specific criteria. Journal of the American Heart Association, 8(17), e012307. (doi: 10.1161/JAHA.119.012307) (PMID:31431112) (PMCID:PMC6755854)